Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A3E5A59
Thu, 14.11.2024
SYNBIOTIC SE
The acquisition of WEECO Pharma by the European hemp and cannabis group SYNBIOTIC SE (ISIN DE000A3E5A59 | WKN A3E5A5) is proving to be a valuable deal in the truest sense of the word. WEECO Pharma is well above the previously planned revenue target for 2024, at EUR 6.75 million as of the end of October 2024. Revenues of over EUR 8 million are expec [ … ]
Fri, 27.09.2024
SYNBIOTIC SE
The Annual General Meeting of SYNBIOTIC SE (ISIN DE000A3E5A59 | WKN A3E5A5) has confirmed the strategic growth course of the European industrial hemp and cannabis company group with an overwhelming majority. At the virtual Annual General Meeting on Friday, 20 September 2024, the shareholders unreservedly approved the plans for the current and comin [ … ]
Tue, 17.09.2024
SynBiotic SE
Company Name:
SynBiotic SE
ISIN:
DE000A3E5A59
Reason for the research:
Update
Recommendation:
BUY
from:
17.09.2024
Target price:
EUR 12.40
Last rating change:
Analyst:
Henry Wendisch
SynBiotic transformation: Reaching new operational high(t)sTopic: The new CEO Daniel Kruse has been in charge for roughly one year now. The implem [ … ]
Tue, 17.09.2024
SynBiotic SE
Company Name:
SynBiotic SE
ISIN:
DE000A3E5A59
Reason for the research:
Update
Recommendation:
BUY
from:
17.09.2024
Target price:
EUR 12.40
Last rating change:
Analyst:
Henry Wendisch
SynBiotic transformation: Reaching new operational high(t)sTopic: The new CEO Daniel Kruse has been in charge for roughly one year now. The implem [ … ]
Tue, 17.09.2024
SynBiotic SE
Company Name:
SynBiotic SE
ISIN:
DE000A3E5A59
Reason for the research:
Update
Recommendation:
BUY
from:
17.09.2024
Target price:
EUR 12.40
Last rating change:
Analyst:
Henry Wendisch
SynBiotic transformation: Reaching new operational high(t)sTopic: The new CEO Daniel Kruse has been in charge for roughly one year now. The implem [ … ]
Fri, 16.08.2024
SYNBIOTIC SE
The Annual General Meeting of SYNBIOTIC SE (ISIN DE000A3E5A59 | WKN A3E5A5), one of Europe's leading industrial hemp and cannabis companies, will take place on Friday, 20 September 2024.
In the run-up to the Annual General Meeting, Daniel Kruse, CEO of SYNBIOTIC, gave an initial outlook on current developments and figures: "WEECO Pharma has achieve [ … ]
Thu, 23.05.2024
SYNBIOTIC SE
The leading European industrial hemp and cannabis group SYNBIOTIC is increasing its public presence. "We want to be even more visible and approachable in the professional world and for our investors," explains Daniel Kruse, CEO of SYNBIOTIC. "The aim is to position the enormous potential of hemp in the centre of society. It's time to end the demoni [ … ]
Thu, 23.05.2024
SYNBIOTIC SE
The leading European industrial hemp and cannabis group SYNBIOTIC is increasing its public presence. "We want to be even more visible and approachable in the professional world and for our investors," explains Daniel Kruse, CEO of SYNBIOTIC. "The aim is to position the enormous potential of hemp in the centre of society. It's time to end the demoni [ … ]
Wed, 08.05.2024
SYNBIOTIC SE
The German industrial hemp and cannabis group SYNBIOTIC SE acquires WEECO Pharma GmbH from Hildesheim/Germany. The merger makes SYNBIOTIC one of the most important players on the German and European market for medicinal cannabis.
"With WEECO Pharma, our group of companies now has a full range of high-quality cannabis flowers. Together with our othe [ … ]
Thu, 25.04.2024
SYNBIOTIC SE
The Federal Ministry for Economic Affairs and Climate Protection (BMWK) is funding a Hanf Farm project in the field of industrial bio-economy with 1.6 million euros. The official funding decision has now been handed over to Managing Director Rafael Dulon and Project Manager Michael Bieder by State Secretary Stefan Wenzel at the Hanover Trade Fair. [ … ]